Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVNS
3551
DELISTED
Avanos Medical
AVNS
| $785K | ﹤0.01% |
69,938
+5,856
| +9% | +$67K |
|
3552
Regional Management Corp
RM
$300M
| $785K | ﹤0.01% |
20,262
+257
| +1% | +$9.95K |
|
3553
Heartland Express
HTLD
$982M
| $785K | ﹤0.01% |
86,942
+14,378
| +20% | +$120K |
|
|
EB
3554
DELISTED
Eventbrite
EB
| $785K | ﹤0.01% |
176,293
+11,466
| +7% | +$35.5K |
|
3555
Sturm, Ruger & Co
RGR
$599M
| $784K | ﹤0.01% |
24,010
-1,151
| -5% | -$42.7K |
|
3556
Criteo S.A. Ordinary Shares
CRTO
$887M
| $784K | ﹤0.01% |
38,032
+20,727
| +120% | +$429K |
|
|
AEVA
3557
Aeva Technologies
AEVA
$1.66B
| $782K | ﹤0.01% |
58,852
+15,021
| +34% | +$214K |
|
3558
Solid Biosciences
SLDB
$980M
| $779K | ﹤0.01% |
138,136
-20,966
| -13% | -$114K |
|
3559
Fiverr
FVRR
$317M
| $778K | ﹤0.01% |
39,392
+34,713
| +742% | +$748K |
|
3560
CALL
Danaher
DHR
$143B
| $778K | ﹤0.01% |
3,400
-6,900
| -67% | -$1.52M |
|
3561
ACNB Corp
ACNB
$660M
| $777K | ﹤0.01% |
16,062
+1,542
| +11% | +$72.8K |
|
|
RC
3562
Ready Capital
RC
$294M
| $774K | ﹤0.01% |
355,110
+15,493
| +5% | +$43.4K |
|
3563
Cass Information Systems
CASS
$750M
| $772K | ﹤0.01% |
18,584
+1,304
| +8% | +$53.1K |
|
|
FRGE
3564
DELISTED
Forge Global Holdings
FRGE
| $769K | ﹤0.01% |
17,251
+3,130
| +22% | +$106K |
|
3565
Western New England Bancorp
WNEB
$282M
| $769K | ﹤0.01% |
60,906
+2,610
| +4% | +$31.4K |
|
3566
Zentalis Pharmaceuticals
ZNTL
$307M
| $767K | ﹤0.01% |
568,443
+406,973
| +252% | +$592K |
|
3567
MVB Financial
MVBF
$396M
| $765K | ﹤0.01% |
29,621
-5,629
| -16% | -$149K |
|
3568
Quanterix
QTRX
$140M
| $764K | ﹤0.01% |
120,203
+52,934
| +79% | +$329K |
|
3569
Clean Energy Fuels
CLNE
$399M
| $764K | ﹤0.01% |
363,605
+38,209
| +12% | +$93.5K |
|
3570
Direxion Daily 7-10 Year Treasury Bull 3X ETF
TYD
$32.3M
| $763K | ﹤0.01% |
+30,000
| New | +$782K |
|
3571
MeiraGTx Holdings
MGTX
$1.27B
| $761K | ﹤0.01% |
95,730
+11,729
| +14% | +$97.5K |
|
3572
CALL
Quanta Services
PWR
$102B
| $760K | ﹤0.01% |
+1,800
| New | +$791K |
|
3573
Columbia Financial
CLBK
$1.22B
| $758K | ﹤0.01% |
48,801
+9,223
| +23% | +$143K |
|
3574
SB Financial Group
SBFG
$174M
| $758K | ﹤0.01% |
34,053
+2,458
| +8% | +$50.9K |
|
3575
Bank7 Corp
BSVN
$500M
| $757K | ﹤0.01% |
18,475
+853
| +5% | +$36.4K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.